¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug development pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • sulfa drug
    ¼úÆÄÁ¦
  • sympathomimetic drug
    ±³°¨½Å°æÈïºÐÁ¦
  • synthetic drug
    ÇÕ¼º¾à
  • vasoactive drug
    Ç÷°üÀÛ¿ë¾à
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • narcotic drug
    ¸¶¾à
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • orphan drug
    Èñ±ÍÀǾàǰ
  • parasympathetic drug
    ºÎ±³°¨½Å°æ¾à
  • parasympathomimetic drug
    ºÎ±³°¨ÈïºÐÁ¦
  • prokinetic drug
    À§Àå¿îµ¿ÃËÁøÁ¦
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • sulfa drug
    ¼úÆÄÁ¦
  • sympathomimetic drug
    ±³°¨½Å°æÈïºÐÁ¦
  • synthetic drug
    ÇÕ¼º¾à
  • topical drug
    ±¹¼Ò¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • vasoactive drug
    Ç÷°üÀÛ¿ë¾à
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý.
  • bacterium, drug resistant
    ¾àÁ¦³»¼º¼¼±Õ
  • barbiturate drug
    ¹Ù¸£ºñÅõ¸£»ê¿°¾à.
  • biological drug
    »ý¹°ÇÐÀû Á¦Á¦(?Ì¡?).
  • biological drug
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • bioreductive drug
    »ýüȯ¿ø¼º¾àÁ¦, -¾à¹°
  • bullous drug eruption
    ¼öÆ÷¼º ¾àÁø(¡­å·òÖ)
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • cardiotropic drug
    ½ÉÀåģȭ¼º ¾àÁ¦
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug(=enhancer)
    ÀÎÁö±â´ÉȰ¼ºÁ¦(ìãò±Ñ¦ÒöüÀàõð¥)
  • common drug =c. medicament
    º¸Åë¾à(ÜÅ÷×å·).
  • competitive drug
    °æÇÕ¾à(Ìæùêå·).
  • crude drug
    »ý¾à(ßæå·), Á¶¾à.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
devel development
EDDS electronic development delivery system
EGDF embryonic growth and development factor
ERDA Energy Research and Development Administration
ESHEL Association for Planning and Development of Services for the Aged in Israel
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
CDER Center for Drug Evaluation and Research
CIDR Controlled Internal Drug Release
DARP Drug Abuse Reporting Program
DATOS Drug Abuse Treatment Outcome Study
DAWN Drug Abuse Warning Network
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug-induced psychosis
    ¾à¹° À¯¹ß Á¤½ÅÁõ
  • drug-induced rhinitis
    ¾à¹° ºñ¿°, ¾à¹°¼º ºñ¿°
    µ¿ÀǾî=rhinitis medicamentosa.
  • drug-induced thrombocytopenic purpura
    ¾à¹°¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ
  • fixed drug enanthema
    °íÁ¤ ¾à¹°¼º Á¡¸·Áø
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • habit forming drug
    ½À°ü¼º ¾àǰ
    À°Ã¼Àû ¶Ç´Â Á¤½ÅÀûÀ¸·Î ÀÇÁ¸¼ºÀ» °®°Ô ÇÏ´Â ¾à¹°.
  • hydantoinlike drug
    È÷´ÜÅäÀÎ¾ç ¾àÁ¦
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦
  • immunosuppressive drug
    ¸é¿ª ¾ïÁ¦Á¦
    »ýüÀÇ ¸é¿ª ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦. »ýü ³»¿¡¼­ ¸é¿ª ¹ÝÀÀÀ¸·Î Á¶Á÷ÀÌ Àå¾Ö¸¦ ¹Þ¾Æ º´ÀÌ ÀϾ´Â °æ¿ì°¡ ÀÖ´Ù. ƯÈ÷, Ç׿ø ¹°ÁúÀÌ ÀÚ±âÀÇ Ã¼¼ººÐÀÏ °æ¿ì¿¡´Â ÀÚ°¡ ¸é¿ª ÁúȯÀ̶ó°í ÇÑ´Ù. ÀÚ°¡ ¸é¿ª Áúȯ¿¡¼­´Â ´ë°³ÀÇ °æ¿ì, Á¦ 1¼±ÅÃÁ¦·Î¼­ ºÎ½Å ÇÇÁú È£¸£¸óÀÌ ¾²À̸ç, À̰Ϳ¡ ÀúÇ×À» ³ªÅ¸³»´Â µî ÇѰ谡 ÀÖÀ» °æ¿ì°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ ¶§ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇÑ º´Å¿¡ ´ëÇÏ¿©, À̸¦ ¾ïÁ¦Çϰí Ä¡·áÇϱâ À§ÇÏ¿© ¸é¿ª ¾ïÁ¦Á¦°¡ »ç¿ëµÈ´Ù. ¶Ç Àå±â ÀÌ½Ä ¶§ °ÅºÎ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§Çؼ­µµ »ç¿ëµÈ´Ù. ¸é¿ª¾ïÁ¦¿¡´Â ±× ¹ÝÀÀ¸¸À» ¾ïÁ¦Çϴ ƯÀÌÇÑ °Í°ú ±×·¸Áö ¾ÊÀº °ÍÀÌ ÀÖÀ¸¸ç, ÀÌ·ÐÀûÀ¸·Î´Â ƯÀÌÇÑ ÂÊÀÇ ÀÛ¿ëÀÌ ¶Ù¾î³ª¾ß ÇϰÚÁö¸¸, ÀÓ»óÀûÀ¸·Î ¾²ÀÌ´Â °ÍÀº °ÅÀÇ ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦ÀÌ´Ù. ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦¿¡´Â »çÀÌŬ·ÎÆ÷½ºÆÄ¹Ìµå, ´ÏÆ®·Î°Õ¸¶½ºÅ¸µå µîÀÇ ¾ËųȭÁ¦, 6-¸Þ¸£Ä°ÅäǪ¸°, ¾ÆÀÚÆ¼¿ÀǪ¸°, ½ÃÅä½Å¾Æ¶óºñ³ë½Ãµå µî°ú °°Àº ´ë»ç ±æÇ×Á¦, ¹ÌÅ丶À̽ŠC, ¾ÇƼ³ë¸¶À̽ŠD µîÀÇ Ç×»ý ¹°Áú, ºÎ½Å ÇÇÁú ½ºÅ×·ÎÀ̵åÁ¦, ºó¾ËÄ®·ÎÀ̵åÁ¦, Ç׸²ÇÁ±¸ Ç÷û µîÀÇ Ç×ü µî ¿©·¯ Á¾·ùÀÇ ¾àÁ¦°¡ ÀÖ´Ù. ÀÌµé ¸é¿ª ¾ïÁ¦Á¦´Â Ç׿ø Àڱؿ¡¼­ Ç×ü »ý¼º±îÁö À̸£´Â µ¿¾È¿¡, ¸ÅÅ©·ÎÆÄÁö¿¡ ÀÇÇÑ Ç׿øÀÇ Å½½Ä, ¸²ÇÁ±¸¿¡ ÀÇÇÑ Ç׿ø ÀνÄ, ¼¼Æ÷ ºÐ¿­, T ¼¼Æ÷¿Í B ¼¼Æ÷ÀÇ ºÐ¿­, Ç×ü »ý¼º µî ¸î °¡Áö °úÁ¤À» ÀúÇØ½ÃÅ´À¸·Î½á ¸é¿ª¾ïÁ¦¸¦ ¾ß±â½ÃŲ´Ù. ´ëºÎºÐÀÌ Ç×Á¾¾ç Ȱ¼ºÀ» °¡Áö°í À־, DNA
  • individual drug
    °³°³ÀÎ ¾à¹°
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
drug-induced cholestasis <hepatology> A condition where a drug is interfering with the normal flow of bile from the liver to the gut via the biliary tract. The end result is jaundice.
Origin: Gr. Stasis = stoppage
(27 Sep 1997)
drug-induced diarrhoea <gastroenterology> Diarrhoea may be produced by several mechanisms. Laxatives may produce diarrhoea by increasing the flow of water into the intestine or by increasing the intestinal motility.
Antibiotic medications can cause diarrhoea by killing the normal bacteria that live in the intestine and help us digest our food. Some drugs produce diarrhoea as a side effect or as drug toxicity.
(27 Sep 1997)
drug-induced disease <pharmacology> A toxic reaction to or morbid condition resulting from the administration of a drug.
(05 Mar 2000)
drug-induced eosinophilic lung disease <radiology> Diffuse reticular pattern: nitrofurantoin, Loeffler-like pattern: penicillin, sulfonamides, ASA, para-ASA, imipramine, HCTZ, cromolyn sodium see: eosinophilic lung disease
(12 Dec 1998)
drug-induced hepatitis <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug.
Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives.
(27 Sep 1997)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
drug-induced tremor <neurology, pharmacology> A drug-induced condition where there is shaking (tremor) of the extremities that is increased with purposeful movement.
Drugs known to induce tremor include: theophylline, Alupent, cyclosporine, amphetamines, lithium and caffeine.
(27 Sep 1997)
drug industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
(12 Dec 1998)
drug information services Services providing pharmaceutic and therapeutic drug information and consultation.
(12 Dec 1998)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
drug labelling Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
(12 Dec 1998)
drug monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
(12 Dec 1998)
drug, over-the-counter Drug for which a prescription is not needed.
(12 Dec 1998)
drug packaging Containers, packaging, and packaging materials for drugs and biological products. These include those in ampule, capsule, tablet, solution or other forms. Packaging includes immediate-containers, secondary-containers, and cartons. In the united states, such packaging is controlled under the federal food, drug, and cosmetic act which also stipulates requirements for tamper-resistance and child-resistance. Similar laws govern use elsewhere. drug labeling is also available.
(12 Dec 1998)
drug pathogenesis The production of morbid symptoms by drugs.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á